Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SCD | O00767 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3780422 | 0.78 | KMT2A (0.44) | POLBSMN1; SMN2LMNASCDHTT | |
| SCHEMBL5132080 | 0.74 | CYP19A1 (0.49) | SMN1; SMN2LMNAHTTKDM4ETDP1 | |
| SCHEMBL5952426 | 0.74 | ALDH1A1 (0.59) | POLBSMN1; SMN2LMNAHTTMAPK1 | |
| SCHEMBL505220 | 0.74 | RXFP1 (0.69) | SMN1; SMN2LMNAHTTRXFP1KDM4E | |
| SCHEMBL30022965 | 0.74 | RXFP1 (0.69) | SMN1; SMN2LMNAHTTRXFP1KDM4E | |
| SCHEMBL2647267 | 0.73 | SMN1; SMN2 (0.63) | POLBSMN1; SMN2LMNAHTTTSHR | |
| SCHEMBL7751896 | 0.72 | ALDH1A1 (0.56) | POLBSMN1; SMN2LMNAHTTMAPK1 | |
| SCHEMBL26657545 | 0.71 | IDH1 (0.66) | POLB | |
| SCHEMBL2647658 | 0.71 | SMN1; SMN2 (0.63) | POLBSMN1; SMN2LMNAHTTTSHR | |
| SCHEMBL5000568 | 0.71 | PTGDR2 (0.47) | LMNASCDTDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443092-B1 | BICYCLIC AND TRICYCLIC COMPOUNDS AS KAT II INHIBITORS | PFIZER (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | KAT2A, KAT2B, KAT6B | POLB 287/4885SMN1; SMN2 3284/4885LMNA 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.